Kavanagh Tomas, Balcomb Kaleah, Trgovcevic Stephanie, Nementzik Laura, Kanshin Evgeny, Halliday Glenda, Ueberheide Beatrix, Drummond Eleanor
Brain and Mind Centre and School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
Proteomics Laboratory, Division of Advanced Research Technologies and Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, New York, USA.
Alzheimers Dement. 2025 Jun;21(6):e70401. doi: 10.1002/alz.70401.
Primary tauopathies, including corticobasal degeneration (CBD), Pick's disease (PiD), and progressive supranuclear palsy (PSP), have aggregated tau pathology in the brain. Many other proteins are likely altered in disease; however, these have not been well characterized.
We performed sarkosyl fractionation of post mortem human brain tissue to enrich soluble and insoluble proteins from CBD, PiD, and PSP cases (n = 5/group). We assessed differences in the soluble fraction, insoluble fraction, and protein solubility changes between diseases, followed by enrichment and correlation analysis.
CBD and PiD showed the greatest proteomic similarity in both the soluble and insoluble fractions, while PSP was the most divergent in comparison to other diseases. We observed critical changes in the solubility of lysosomal regulators, postsynaptic proteins, the extracellular matrix (ECM), and mitochondrial proteins.
We have contrasted the solubility patterns of proteins across three tauopathies for the first time. Protein solubility differences reveal divergence in disease processes.
Tau isoforms are differentially soluble in primary tauopathies PSP proteomics profile was the most divergent of the tauopathies examined SORT1 is highly insoluble in CBD and aggregates to different extents in tauopathies There are shifts in solubility for key signalling pathways; ROCK1 and JAK2 Unique lysosomal proteins are more insoluble in distinct tauopathies.
原发性tau蛋白病,包括皮质基底节变性(CBD)、匹克病(PiD)和进行性核上性麻痹(PSP),在大脑中存在tau蛋白聚集性病理改变。疾病中许多其他蛋白质可能也发生了改变;然而,这些尚未得到充分表征。
我们对死后的人脑组织进行了 Sarkosyl 分级分离,以富集来自 CBD、PiD 和 PSP 病例(每组 n = 5)的可溶性和不溶性蛋白质。我们评估了疾病之间可溶性部分、不溶性部分以及蛋白质溶解度变化的差异,随后进行了富集和相关性分析。
CBD 和 PiD 在可溶性和不溶性部分均显示出最大的蛋白质组相似性,而与其他疾病相比,PSP 的差异最大。我们观察到溶酶体调节因子、突触后蛋白、细胞外基质(ECM)和线粒体蛋白的溶解度发生了关键变化。
我们首次对比了三种tau蛋白病中蛋白质的溶解度模式。蛋白质溶解度差异揭示了疾病过程中的差异。
tau 异构体在原发性 tau 蛋白病中的溶解度不同 PSP 的蛋白质组学特征在所研究的 tau 蛋白病中差异最大 SORT1 在 CBD 中高度不溶,在 tau 蛋白病中聚集程度不同 关键信号通路的溶解度发生变化;ROCK1 和 JAK2 独特的溶酶体蛋白在不同的 tau 蛋白病中更不溶。